Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: A meta-analysis of 8 randomized trials

► Abciximab has been shown to improve survival in STEMI patients undergoing primary angioplasty. ► Intracoronary administration, by providing of larger amount of drug at the occlusion, seems to be more effective as compared to intravenous administration. ► Contrasting data have been reported in small randomized trials. ► This is meta-analysis of 8 randomized trials shows that intracoronary abciximab is safe. Despite benefits in myocardial perfusion, it does not improve survival.